Q80K Polymorphism Screening
Polymorphisms are natural genetic variations that occur in a population at variable frequencies. The Q80K polymorphism in hepatitis C virus (HCV) has been observed in 35% of patients infected with HCV genotype 1 and in greater than 40% of patients with HCV genotype 1a in the United States, where genotype 1a represents approximately 75% of HCV genotype 1 infections overall.1 The Q80K polymorphism has been shown to alter the NS3/4A protease in a way that substantially reduces the efficacy of simeprevir (Olysio®), an FDA-approved protease inhibitor indicated for use with pegylated interferon alpha and ribavirin (peg-IFN/RBV).1
The HCV GenoSure® NS3/4A Assay can be used to screen for the Q80K polymorphism in patients with HCV genotype 1. HCV GenoSure NS3/4A features include:
1. Olysio [Highlights of Prescribing Information]. Titusville, NJ: Janssen Therapeutics; 2013.
Olysio is a registered trademark of Janssen R&D Ireland Corporation.